莫西沙星联合盐酸丙卡特罗治疗医院获得性肺炎的效果及预后分析

Efficacy and prognosis of moxifloxacin combined with procaterol in the treatment of hospitalacquired pneumonia

目的观察研究莫西沙星联合盐酸丙卡特罗治疗医院获得性肺炎的效果及预后。方法回顾性分析2012年3月至2013年7月本院接诊的112例医院获得性肺炎患者的临床资料。按照随机数表法分为观察组和对照组,每组各56例。观察组患者采用莫西沙星联合盐酸丙卡特罗治疗,对照组患者采用阿奇霉素治疗。对比两组患者临床疗效、住院时间、治疗时间、不良反应发生情况以及预后痰培养相关情况。结果观察组患者治疗总有效率明显高于对照组,住院时间和治疗时间明显短于对照组(P<0.05)。观察组患者不良反应发生率为17.86%(10/56),对照组为33.93%(19/56),两组比较差异无显著性(P>0.05)。观察组预后痰培养转阴结果明显多于对照组,且阳性结果明显减少,均明显少于对照组(P<0.05)。结论莫西沙星联合盐酸丙卡特罗治疗医院获得性肺炎疗效可靠,预后良好,缩短了患者治疗时间和住院时间,值得临床推广应用。

ObjectiveTo observe and study the efifcacy and prognosis of moxilfoxacin combined with procaterol in the treatment of hospital-acquired pneumonia.Method112 cases of hospital-acquired pneumonia patients from March 2012 to July 2013 in our hospital admissions were analyzed retrospectively. According to a random table number method they were divided into observation group and control group, 56 cases in each group. Observation group were treated by moxilfoxacin combined with procaterol, control group were treated by azithromycin. Analyzed and compared the clinical efifcacy, hospital-staying time, duration of treatment and adverse reactions between the two groups of patients.ResultThe total effective rate of the observation group was signiifcantly higher than control group, the hospital-staying time and treatment time were significantly shorter than control group （P〈0.05）. The incidence of adverse reactions in the observation group was 17.86% （10/56）, control group was 33.93% （19/56）, the difference between the two groups was not signiifcant （P〉0.05）. The sputum culture negative results in the observation group was signiifcantly more than control group, the positive results were significantly reduced, all were less than control group （P〈0.05）.ConclusionMoxilfoxacin combined with procaterol in the treatment of hospital-acquired pneumonia has reliable effective, and the prognosis is good, shorten the treatment time and hospital-staying time of patients, worthy of promotion and application.